Actively Recruiting
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
Led by Dana-Farber Cancer Institute · Updated on 2025-09-23
32
Participants Needed
5
Research Sites
439 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
A
Adenoid Cystic Carcinoma Research Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)
CONDITIONS
Official Title
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed adenoid cystic carcinoma (ACC) with distant metastases
- One to five detectable metastatic sites for Cohort 1; at least one non-bone metastatic site for Cohort 2
- Maximum size of brain lesions is 3 cm for Cohort 1
- All metastatic sites in Cohort 1 must be suitable for SBRT treatment
- Primary tumor controlled or stable without progression within 6 months prior to enrollment for Cohort 1
- Age 18 years or older
- ECOG performance status of 0-2
- Prior systemic therapy allowed except no treatment within 2 weeks before or during SBRT
- Ability to understand and sign informed consent
- Women of childbearing potential must have negative pregnancy test before treatment
- Men sexually active with women of childbearing potential must use contraception during and 1 month after treatment
You will not qualify if you...
- Systemic therapy for ACC within 2 weeks before enrollment for Cohort 1
- Need for urgent surgery for metastatic brain or spine disease
- Use of alternative local ablative therapies for planned SBRT sites before enrollment for Cohort 1
- Bone metastasis in femur requiring surgical stabilization
- Active progressing disease larger than 1 cm not suitable for SBRT for Cohort 1
- Pregnant or breastfeeding women
- Uncontrolled illnesses such as severe heart failure, unstable angina, arrhythmia, or psychiatric/social issues limiting compliance
- Other progressing malignancies requiring treatment, except certain skin cancers, in situ cervical cancer, or low-risk prostate cancer under surveillance
- History of other cancers in remission less than 2 years ago
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University of California, San Francisco
San Francisco, California, United States, 94158
Actively Recruiting
2
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
3
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
J
Jonathan D Schoenfeld, MD, MPH
CONTACT
G
Glenn J Hanna, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here